About ublituximab
Anti-CD20 monoclonal antibody
Used for
- Treats relapsing forms of multiple sclerosis in adults.
Usual adult dose
150 mg by intravenous infusion initially; 450 mg two weeks later, then 450 mg every 24 weeks.
Common side effects
- Infusion reactions
- Upper respiratory infections
- Headache
- Herpes infections
Important warnings
- Infusion reactions can be serious or life-threatening.
- Screen for hepatitis B before treatment; active infection may worsen.
- Treatment can increase infection risk and reduce vaccine responses.
- Live vaccines are not recommended during treatment or until B cells recover.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for six months after the last dose.
Breastfeeding
It is not known whether ublituximab passes into breast milk. Discuss potential risks and benefits with a healthcare professional.
Interactions
- Live vaccines may cause infection and should be avoided.
- Other immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.